Docetaxel
A taxane chemotherapy drug derived from the Pacific yew tree, used to treat breast, lung, prostate, gastric, and head and neck cancers by stabilizing microtubules during cell division, preventing cancer cells from splitting into two. It is given intravenously and commonly causes hair loss, fluid retention, and low blood counts. Patients typically receive a corticosteroid premedication to reduce fluid retention and hypersensitivity reactions.
Peso Molecular
807,9000 g/mol
LogP
1,60
TPSA
224,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
InChI
InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1
Molecular Formula
C43H53NO14
HBD / HBA
5 / 14
Ligações Rotacionáveis
13
Átomos Pesados
58
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A taxane chemotherapy drug derived from the Pacific yew tree, used to treat breast, lung, prostate, gastric, and head and neck cancers by stabilizing microtubules during cell division, preventing cancer cells from splitting into two. It is given intravenously and commonly causes hair loss, fluid retention, and low blood counts. Patients typically receive a corticosteroid premedication to reduce fluid retention and hypersensitivity reactions.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Docetaxel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545252. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 148124. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="docetaxel"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/docetaxel/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/docetaxel/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/docetaxel/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="docetaxel"></drugfyi-drug>